Drug-Induced Liver Injury (DILI)
Drug-induced liver injury (DILI) is one of the most serious medication side effects and a leading cause of acute liver failure. This guide explains which drugs are most commonly responsible, how to recognize DILI early, and how the liver is protected through monitoring.
What Is Drug-Induced Liver Injury?
Drug-induced liver injury (DILI) is damage to the liver caused by prescription drugs, over-the-counterOver-the-Counter Medications that can be purchased without a prescription, deemed safe for consumer use when following the label directions. The FDA determines OTC status based on a drug's safety profile, abuse potent
Despite its severity, DILI is often missed or diagnosed late because its symptoms closely mimic those of viral hepatitis, autoimmune liver disease, and biliary obstruction. Awareness of which medications carry hepatotoxic risk — and what warning signs to watch for — is essential for anyone taking long-term medications.
How Drugs Damage the Liver
The liver is the primary organ for drug metabolism. Most drugs enter the bloodstream through the gut, pass through the liver via the portal circulation, and are chemically modified there into forms that can be eliminated from the body. This exposes hepatocytes (liver cells) to high concentrations of both the parent drug and its metabolic byproducts.
Liver damage can occur through several mechanisms:
Direct Hepatotoxicity (Intrinsic DILI)
Some drugs are inherently toxic to liver cells in a dose-dependent manner. Acetaminophen (paracetamol) is the classic example: at therapeutic doses it is safe; at doses exceeding 7.5–10 grams in adults, it overwhelms the liver's detoxification capacity and causes massive cell death. This type of DILI is predictable, reproducible in animal models, and occurs in most people exposed to sufficient drug concentrations.
Idiosyncratic DILI
The more common and clinically challenging form of DILI is idiosyncratic — it occurs unpredictably in a small subset of patients, regardless of dose, after a latency period of days to months. Idiosyncratic DILI is thought to involve immune-mediated reactions (the drug or its metabolite acts as a hapten, triggering an immune attack on hepatocytes) or mitochondrial dysfunction in genetically susceptible individuals.
Common Culprit Medications
Over 1,000 drugs and herbal products have been associated with DILI. The highest-risk categories include:
Analgesics and anti-inflammatory drugs: - Acetaminophen (dose-dependent; most common cause of acute liver failure in the US) - NSAIDs (diclofenac carries notable hepatotoxic risk; sulindac, piroxicam also implicated)
Antibiotics: - Amoxicillin-clavulanate (augmentin) — the most common cause of antibiotic-related DILI - Fluoroquinolones (ciprofloxacin, moxifloxacin) - Isoniazid (used for tuberculosis; significant hepatotoxic risk, especially with alcohol use) - Nitrofurantoin (risk increases with chronic use)
Cardiovascular medications: - Statins (generally mild and reversible; severe DILI is rare but possible) - Amiodarone (can cause steatohepatitis with long-term use) - Methyldopa, hydralazine
Psychotropic medications: - Valproate (anticonvulsant; risk highest in young children) - Phenytoin - Chlorpromazine (cholestatic pattern)
Immunosuppressants and biologics: - Methotrexate (cumulative dose-dependent fibrosis with long-term use) - Azathioprine, mercaptopurine
Herbal and dietary supplements: - Kava kava, pyrrolizidine alkaloids (comfrey), green tea extract, anabolic steroids - These are a growing and under-recognized cause of DILI; always disclose supplement use to your healthcare provider.
Recognizing DILI: Symptoms and Lab Findings
DILI can present in three main patterns, which overlap with different underlying liver diseases:
| Pattern | AST/ALT | ALP | Bilirubin | Clinical Presentation |
|---|---|---|---|---|
| Hepatocellular | Very elevated (>5x ULN) | Normal or mildly elevated | May be elevated | Fatigue, nausea, jaundice |
| Cholestatic | Mildly elevated | Elevated (>2x ULN) | Elevated | Jaundice, itching, pale stools |
| Mixed | Both elevated | Both elevated | Variable | Mixed symptoms |
Symptoms to watch for: - Yellowing of the skin or whites of the eyes (jaundice) - Dark urine (tea- or cola-colored) - Light-colored or pale stools - Fatigue and weakness - Upper right abdominal pain or tenderness - Nausea, vomiting, loss of appetite - Itching (pruritus) — especially with cholestatic pattern
Many cases of mild DILI are asymptomatic and discovered only through routine blood tests showing elevated liver enzymes. This underscores the importance of lab monitoring during therapy with hepatotoxic drugs.
The Hy's Law Rule
Hy's Law is a clinical benchmark used to identify drug-induced liver injury cases with high risk of progressing to fatal outcomes. A case meets Hy's Law criteria when:
- The drug causes hepatocellular injury (AST/ALT ≥ 3× upper limit of normal).
- The patient also develops jaundice (bilirubin ≥ 2× upper limit of normal).
- No other cause (viral hepatitis, pre-existing liver disease, biliary obstruction) explains the findings.
Cases meeting Hy's Law criteria carry a mortality risk of approximately 10% if the drug is not discontinued. Regulators use Hy's Law during clinical development to flag drugs that should not be approved or require additional monitoring requirements.
Risk Factors for DILI
Not everyone taking a potentially hepatotoxic drug will develop DILI. Several factors increase individual susceptibility:
- Alcohol use: Chronic alcohol consumption depletes glutathione (a critical antioxidant in liver cells) and induces CYP2E1, increasing the production of toxic acetaminophen metabolites. Even moderate alcohol intake significantly raises DILI risk with acetaminophen.
- Pre-existing liver disease: Cirrhosis, fatty liver disease, or chronic hepatitis B/C reduce the liver's functional reserve.
- Genetic polymorphisms: Variants in drug-metabolizing enzymes (CYP2C9, CYP2D6, UGT1A) and immune response genes (HLA alleles) are associated with idiosyncratic DILI risk for specific drugs.
- Age: The elderly metabolize drugs more slowly and have reduced hepatic blood flow.
- Nutritional status: Fasting or malnutrition depletes glutathione, increasing vulnerability.
- Drug interactions: Two hepatotoxic drugs taken together can have additive or synergistic toxicity.
- Pregnancy: Some forms of DILI (e.g., tetracycline-associated fatty liver) are more severe in pregnancy.
Liver Function Monitoring During Therapy
For drugs with known hepatotoxic potential, healthcare providers routinely monitor liver function tests (LFTs), including:
- AST (aspartate aminotransferase) and ALT (alanine aminotransferase): Elevated with hepatocellular damage. ALT is more liver-specific.
- ALP (alkaline phosphatase): Elevated with cholestatic injury or biliary obstruction.
- Total bilirubin: Indicates impaired bile processing or cell destruction.
- GGT (gamma-glutamyl transferase): Sensitive marker of liver enzyme inductionEnzyme Induction
The process by which a drug increases the production of metabolizing enzymes (particularly CYP450), leading to faster breakdown of itself or other drugs. This can reduce the effectiveness of co-admini
or damage. - PT/INR: The liver produces clotting factors; a rising INR suggests worsening liver function.
Monitoring schedules vary by drug. Isoniazid typically requires monthly LFTs during the initial months of therapy. Methotrexate requires periodic liver biopsy for long-term users above a cumulative dose threshold. Statins generally require baseline LFTs but routine monitoring is not recommended in the absence of symptoms.
Treatment and Recovery
The primary treatment for DILI is discontinuation of the offending drug. For most cases of idiosyncratic DILI, liver enzymes normalize within weeks to months after stopping the drug. Recovery is the rule rather than the exception.
Specific interventions include: - N-acetylcysteine (NAC): The antidote for acetaminophen overdose. Must be given within 8–16 hours of ingestion for maximum benefit. NAC replenishes hepatic glutathione and has shown benefit in some non-acetaminophen DILI cases as well. - Corticosteroids: May be used in immune-mediated DILI with autoimmune features. - Liver transplantation: For acute liver failure that does not recover with medical management. - Supportive care: Fluid balance, nutrition, management of complications (coagulopathy, encephalopathy).
Approximately 5–10% of DILI cases progress to chronic liver disease despite drug discontinuation. Repeat exposure to the causative drug is strongly contraindicated.
Hepatic Dosing Adjustments
For patients with pre-existing liver disease, many drugs require hepatic dosing adjustments. The liver is responsible for metabolizing a large proportion of drugs, and reduced liver function means:
- Drugs may accumulate to higher-than-intended levels.
- Prodrugs (inactive compounds that must be metabolized to active form) may be less effective.
- Drug half-lives may be significantly prolonged.
Clinicians use the Child-Pugh score or MELD score to assess severity of liver disease and guide dosing. Some drugs are contraindicated entirely in severe hepatic impairment. Always inform your prescriber and pharmacist of any liver condition before starting a new medication.
This guide is for educational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making changes to your medication regimen.